drugset / Trial / NCT01827618

Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

NCT01827618

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer.

Timeline

Start
2012-04
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 3 mg Oral